文献速递类风湿关节炎痛风与晶体性关节病

类风湿关节炎中合并高尿酸血症与痛风:与合并症、疾病活动度及死亡率的关联

Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-06-07

本研究基于纵向类风湿关节炎(RA)队列,分析合并高尿酸血症和痛风与RA疾病特征、治疗及生存的关联。1999例RA患者中17%血清尿酸>6.8 mg/dl,6.1%诊断为痛风;调整年龄性别后中等高尿酸血症与心血管病死亡风险增加相关(HR 1.56),但进一步调整合并症后关联减弱且不显著,未发现与全因死亡相关。

要点

  • RA患者中高尿酸血症和痛风常见,但与RA疾病活动度或治疗无显著关联。
  • 中等高尿酸血症(>6.8至≤8 mg/dl)与心血管病死亡风险增加相关(HR 1.56)。
  • 该风险在进一步调整合并症后减弱且不显著,提示由合并症驱动。

核心结论

  • RA患者中高尿酸血症与心血管病死亡风险存在较强关联,但该风险似乎由过多的合并症驱动。

研究设计与样本

  • 纵向RA研究,纳入1999例RA参与者,按痛风及血清尿酸状态分组比较基线特征、疾病活动度、治疗和合并症,并用多变量生存分析评估基线尿酸与全因及心血管病死亡的关系。

主要发现

  • 1999例RA参与者中341例(17%)血清尿酸>6.8 mg/dl,121例(6.1%)诊断为痛风。
  • 入组时血清尿酸浓度或痛风与RA疾病活动度或治疗无显著关联,例外是痛风患者更可能使用柳氮磺吡啶、较少使用非甾体抗炎药。
  • 调整年龄和性别后,中等高尿酸血症(血清尿酸>6.8至≤8 mg/dl)与心血管病死亡风险增加相关(HR 1.56 [95%CI 1.11-2.21])。
  • 进一步调整高尿酸血症更常伴随的合并症后,上述关联减弱且不显著;血清尿酸>8.0 mg/dl的结果类似但任何模型均未达统计学显著。
  • 基线血清尿酸浓度与全因死亡率无关联。

关键数值与推荐

  • 高尿酸血症定义为血清尿酸>6.8 mg/dl,本队列中占17%。
  • 痛风诊断在本队列中占6.1%。
  • 中等高尿酸血症(>6.8至≤8 mg/dl)与心血管病死亡的HR为1.56(95%CI 1.11-2.21),调整年龄性别后。

临床怎么用

  • 在RA管理中应关注高尿酸血症和痛风,并将其视为心血管病死亡风险增高的警示信号。
  • 评估高尿酸血症对预后的影响时需充分考虑合并症,因其可能解释大部分心血管病死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although hyperuricemia and gout can complicate the course of rheumatoid arthritis (RA), the impact of these factors on outcomes in RA is unclear. We undertook this study to examine associations of coexistent hyperuricemia and gout with RA disease measures, RA treatments, and survival. METHODS: Participants from a longitudinal RA study were categorized by the presence of gout and serum urate (UA) status. Groups were compared by baseline patient characteristics, RA disease activity, treatments, and comorbidities. Associations of baseline serum UA levels with all-cause and cardiovascular disease (CVD)-related mortality were examined in multivariable survival analyses. RESULTS: Of 1,999 participants with RA, 341 (17%) had serum UA concentrations of >6.8 mg/dl, and 121 (6.1%) were diagnosed with gout. There were no significant associations of serum UA concentration or gout with RA disease activity or treatment at enrollment, with the exception that those with gout were more likely to be receiving sulfasalazine and less likely to be receiving nonsteroidal antiinflammatory drugs. After adjustments for age and sex, moderate hyperuricemia (serum UA >6.8 to ≤8 mg/dl) was associated with an increased risk of CVD-related mortality (hazard ratio 1.56 [95% confidence interval 1.11-2.21]). This association was attenuated and not significant following additional adjustment for comorbidities that more commonly accompany hyperuricemia. Results corresponding with serum UA concentrations of >8.0 mg/dl were similar, although not reaching statistical significance in any model. There were no associations of baseline serum UA concentration with all-cause mortality. CONCLUSION: Our study reports the frequency of hyperuricemia and gout in patients with RA. These results demonstrate strong associations of hyperuricemia with CVD mortality in this population, a risk that appears to be driven by excess comorbidity.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Chiou A, England BR, Sayles H, et al. Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality. Arthritis Care Res (Hoboken). 2020. PMID: 31074584. doi:10.1002/acr.23926

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。